



## **Vaccines for Patients With Immunodeficiencies and Their Efficacy: An Overview in Pandemic Era**

Guest Editors:

**Prof. Dr. Lo Presti Elena**

National Research Council (CNR)  
—Institute for Biomedical  
Research and Innovation (IRIB),  
90146 Palermo, Italy

**Dr. Trizzino Antonino**

Department of Pediatric  
Hematology and Oncology,  
A.R.N.A.S. Civico Di Cristina and  
Benfratelli Hospital, 90127  
Palermo, Italy

Deadline for manuscript  
submissions:

**closed (31 January 2023)**

### **Message from the Guest Editors**

Dear Colleagues, we are pleased to invite you to submit a contribution to this Special Issue

- The aim is to have a comprehensive analysis of types of vaccines in current use for Immunocompromised patients until the latest use for SARS-CoV2 infection. Taking in consideration the advanced technologies rapidly expanded over the last years in computational analysis or the predictive models and in vitro immunoassay, this special issue wants to explore the effectiveness of the vaccines to optimize the development of safety and tolerable protocols for vulnerable patients.
- This Special Issue will collect the following article types: Original research articles, Clinical Case reports, Reviews and Perspective analysis. The Research areas may include the following subjects (but not limited to): Clinical Immunology, Mathematical modeling, Machine learning analysis, Cellular Immunology. Allergology, Virology.

We look forward to receiving your contributions.

Prof. Dr. Lo Presti Elena

Dr. Trizzino Antonino

*Guest Editors*





an Open Access Journal by MDPI

## Editor-in-Chief

### **Prof. Dr. Ralph A. Tripp**

Department of Infectious  
Diseases, College of Veterinary  
Medicine, University of Georgia,  
Athens, GA 30602-7387, USA

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPLus / SciFinder**, and **other databases**.

**Journal Rank:** JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

## Contact Us

*Vaccines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)  
[X@Vaccines\\_MDPI](https://twitter.com/Vaccines_MDPI)